Impact of Lp(a) testing on lipid management

Lp(a) measurement in clinical practice is infrequent even among patients with atherosclerotic cardiovascular disease (ASCVD), though there are signs that testing is becoming more common and that it can lead to increased use of lipid lowering therapies (LLT), according to results of two large US studies.^1,2